Immutep receives French R&D tax credit

Latest News

Immutep (ASX:IMM), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has received a €1,221,906 (~ A$1,910,010) cash rebate from the French Government under its Crédit d’Impôt Recherche scheme.

The 'Crédit d’Impôt Recherche' (CIR), translated to 'Research Tax Credit', is a French government tax incentive by which local companies conducting research and development activities in Europe can be reimbursed 30 per cent of their eligible expenditure.

Immutep qualifies to receive CIR credits through its French subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory at Châtenay-Malabry in southwestern Paris.

The company said the funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.